Integral Molecular Out-Licenses First-in-Class Antibody Panel Targeting SLC2A4 Glucose Transporter

PHILADELPHIA, June 17, 2025 /PRNewswire/ -- Integral Molecular, the industry leader in discovering antibodies against membrane proteins, is pleased to announce that it has out-licensed a panel of highly selective antibodies for the glucose transporter SLC2A4 (also known as GLUT4) for therapeutic development. The transporter has eluded antibody discovery efforts due to its structural complexity, making it inaccessible using traditional antibody discovery methods.

The antibodies licensed by Integral Molecular represent the first-ever monoclonal antibodies described against SLC2A4 and include antibodies specific to the inward-open and outward-open states of the transporter. These molecules were discovered using Integral Molecular's proprietary technology suite, specifically tailored to access difficult membrane protein targets.

Integral Molecular's specialized antibody discovery technologies include:

• MPS Antibody Discovery platform – Elicits robust immune responses even against the most complex proteins and rare epitopes
• Paratope-PLUS™ – Enhances antibody intellectual property and engineering
• Membrane Proteome Array™ – Ensures absolute specificity by screening for off-target binding across a panel of 6,000 native-conformation membrane proteins

"Many diseases remain difficult to treat because the proteins involved in the disease pathway are simply too difficult to target," said Joseph Rucker, PhD, Vice President of R&D at Integral Molecular. "We are thrilled that our platform opens doors to previously untapped targets. We look forward to helping bring SLC2A4-based therapeutics to patients."

Explore Integral Molecular's pipeline of therapeutic antibody assets
available for licensing

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in creating transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on membrane proteins, viruses, and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Press Contact
Integral Molecular
Soma Banik, PhD, Director of Public Relations       
215-966-6061

SOURCE Integral Molecular